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Abstract
Research has found that certain bacteria are associated with human cancers. Their role, however,
is still unclear. Convincing evidence links some species to carcinogenesis while others appear
promising in the diagnosis, prevention or treatment of cancers. The complex relationship between
bacteria and humans is demonstrated by Helicobacter pylori and Salmonella typhi infections. Research
has shown that H. pylori can cause gastric cancer or MALT lymphoma in some individuals. In
contrast, exposure to H. pylori appears to reduce the risk of esophageal cancer in others. Salmonella
typhi infection has been associated with the development of gallbladder cancer; however S. typhi is
a promising carrier of therapeutic agents for melanoma, colon and bladder cancers. Thus bacterial
species and their roles in particular cancers appear to differ among different individuals. Many
species, however, share an important characteristic: highly site-specific colonization. This critical
factor may lead to the development of non-invasive diagnostic tests, innovative treatments and
cancer vaccines.
Introduction
An overwhelming body of evidence has determined that
relationships among certain bacteria and cancers exist.
The bacterial mechanisms involved are as yet unclear.
These gaps in knowledge make it impossible to state the
exact progression of events by which specific bacteria may
cause, colonize or cure cancer. Therefore, many questions
remain. For example, why do infections that are wide
spread appear to cause cancer in only a minority of indi-
viduals? Do certain infective agents initiate or promote
cancer or does an early undetected cancer facilitate the
acquisition of the infection? Can the exposure to or colo-
nization of specific bacteria prevent or treat certain can-
cers? Can the highly site specific colonization of certain
bacteria for a tumor be clinically useful in the diagnosis of
cancer or delivery of a therapeutic agent?
The scope of this review is broad therefore a wide range of
reports is presented. Recent findings that have found asso-
ciations between certain bacterial infections and tumor
development will be discussed as well as genetic factors
that may predispose individuals to "cancer- causing"
infections. Mechanisms thought to be involved with the
carcinogenic, diagnostic and preventive or treatment roles
of bacteria are introduced. As the carcinogenic potential of
viral agents and H. pylori has been reviewed extensively
elsewhere, it will not be included here.
Bacteria and carcinogenesis
It is estimated that over 15% of malignancies worldwide
can be attributed to infections or about 1.2 million cases
per year. Pisani et al. [1] Infections involving viruses, bac-
teria and schistosomes have been linked to higher risks of
malignancy. Although viral infections have been strongly
associated with cancers [2,3]  bacterial associations are
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Helicobacter pylori with both gastric cancer and mucosa-
associated lymphoid tissue (MALT) lymphoma [4-6],
however other species associated with cancers include:
Salmonella typhi and gallbladder cancer [7-10], Streptococ-
cus bovis and colon cancer [11-14] and Chlamydia pneumo-
niae with lung cancer [15-17]. Important mechanisms by
which bacterial agents may induce carcinogenesis include
chronic infection, immune evasion and immune suppres-
sion [18].
It has been shown that several bacteria can cause chronic
infections or produce toxins that disturb the cell cycle
resulting in altered cell growth [15,16,19]. The resulting
damage to DNA is similar to that caused by carcinogenic
agents as the genes that are altered control normal cell
division and apoptosis [20,21]. Processes that encourage
the loss of cellular control may be tumor initiators
(directly causing mutations) or promoters (facilitating
mutations). Tumorigenesis is initiated when cells are
freed from growth restraints, later promotion results when
the immune system is evaded favoring further mutations
and increased loss of cell control. As the tumor prolifer-
ates an increased blood supply is needed resulting in the
organization of blood vessels or angiogenesis. Subsequent
invasion occurs if the tumor breaks down surrounding tis-
sues. The worst outcome is metastasis which results when
cells break away from the tumor and seed tumors at dis-
tant sites [8].
The immune system is an important line of defense for
tumor formation of malignancies that express unique
antigens. Certain bacterial infections may evade the
immune system or stimulate immune responses that con-
tribute to carcinogenic changes through the stimulatory
and mutagenic effects of cytokines released by inflamma-
tory cells. These include reactive oxygen species (ROS),
[22,23], interleukin-8 (IL-8) [11], cyclooxygenase-2
(COX-2), [24], reactive oxygen species (ROS) and nitric
oxide (NO) [25]. Chronic stimulation of these substances
along with environmental factors such as smoking, or a
susceptible host appears to contribute significantly to car-
cinogenesis.
Salmonella typhi and gallbladder cancer
Worldwide annual incidence of gallbladder cancer (GC) is
17 million cases with high incidence rates in certain pop-
ulations. The malignancy is usually associated with gall-
stone disease, late diagnosis, unsatisfactory treatment,
and poor prognosis. The five-year survival rate is approxi-
mately 32 percent for lesions confined to the gallbladder
mucosa and one-year survival rate of 10 percent for more
advanced stages [26]. Over 90 percent of gallbladder car-
cinomas are adenocarcinoma [27] involving gallstones in
78% – 85% of cases [26].
There are several risk factors for gallbladder cancer. The
main associated risk factors include cholelithiasis (espe-
cially untreated chronic symptomatic gallstones), obesity,
reproductive factors, environmental exposure to certain
chemicals, congenital developmental abnormalities of the
pancreatic bile-duct junction and chronic infections of the
gallbladder [26,28]. The interplay of genetic susceptibil-
ity, lifestyle factors and infections in gallbladder carcino-
genesis is still poorly understood [29], however a link has
been specifically proposed between chronic bacterial
infections of the gallbladder and Salmonella typhi [26].
The strongest epidemiological evidence of bacterial onco-
genic potential, aside of Helicobacter pylori, concerns S.
typhi. Infection with this bacterium of typhoid, can lead to
chronic bacterial carriage in the gallbladder [30]. Recent
epidemiological studies have shown that those who
become carriers of S. typhi have 8.47 times the increased
risk of developing carcinoma of the gallbladder compared
with people who have had acute typhoid and have cleared
the infection [26]. These findings agreed with earlier
investigations by Welton et al. [31] and Caygill [30].
A case-control study by Welton et al [31] compared those
who experienced acute infection with S. typhi to those
who subsequently became chronic carriers following the
1922 typhoid outbreak in New York. Carriers were six
times more likely to die of hepatobiliary carcinoma than
matched controls. Additional evidence was found in an
analysis of the 1964 typhoid outbreak in Aberdeen [30].
Their findings also suggested a strong association between
chronic carrier status and hepatobiliary carcinoma. These
studies also agreed, people who contracted typhoid but
did not become carriers were not at higher risk of cancer
[8,26,30,31].
The highest incidence of gallbladder cancer (GC) in the
world is among populations of the Andean area, North
American Indians, and Mexican Americans. In Europe, the
highest rates are found in Poland, the Czech Republic and
Slovakia. The high rates observed in Latin America are pri-
marily in populations with high levels of Indian mixture
[32]. This evidence supports the notion that increased sus-
ceptibility to gallbladder cancer depends on genetic fac-
tors that predispose people to gallbladder cancer either as
primary factors, or secondarily as promoters by favoring
the development of cholesterol gallstones. The highest
mortality rates are in South America, (3.5–15.5 per
100,000) and among Mexican Americans [26]. Incidence
rates of GC in various ethnic groups in the USA confirmed
the worldwide pattern, as GC was substantially more fre-
quent among Hispanic than non-Hispanic white women
and men. Interestingly, compared to non-Hispanic whites
an excess of GC was also reported among American Indi-
ans in New Mexico, in agreement with the excess in inci-Page 2 of 18
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Natives [33]. The malignancy is 3 times higher, however,
among women than men in all populations [26].
Two main pathways to GC exist worldwide. The predom-
inant pathway involves gallstones and resultant cholecys-
titis and affects women to a greater extent than men. The
risk of developing gallstones in response to environmen-
tal factors is genetically determined, as shown by the
marked tendency of gallstones to cluster in families [34].
The other pathway involves an anomalous pancreatobil-
iary duct junction (APBDJ), a congenital malformation of
the biliary tract that is more frequent in Japan, Korea, and
possibly China, than in Western countries [28]. In APBDJ,
the premature junction of common bile and pancreatic
ducts results in regurgitation of pancreatic juice into the
gallbladder, leading to bile stasis and inflammation,
though generally less severe than that resulting from gall-
stones [28].
Currently the prevention of gallbladder cancer in high risk
populations depends upon the diagnosis of gallstones
and removal of the gallbladder. Indeed, a strong inverse
association between number of cholecystectomies and
GC incidence and mortality rates can be found in many
countries. The increase of GC mortality reported in Chile
in the 1980s was related to decreased rates of cholecystec-
tomies [35]. Increased rates led to the removal of gallblad-
ders at risk, and a reduction of GC incidence and mortality
in Europe and the United States [36].
Unfortunately, information about the genetic changes
involved in gallbladder carcinogenesis is limited. Most
studies have focused on gene abnormalities and deletions
("loss of heterozygosity") at chromosomal regions har-
boring known or putative tumor suppressor genes [28]. It
appears, however, that TP53 inactivation has an impor-
tant and early role in gallbladder carcinoma associated
with gallstones and chronic inflammation. This inactiva-
tion would abrogate the tumor suppressor function of the
p53 protein resulting in impairments in cell cycle control,
cellular repair and apoptosis.
In contrast, KRAS mutations are frequent and early events
in tumors associated with APBDJ [28] but detected less
often in gallbladder carcinomas associated with gall-
stones. KRAS is an oncogene that encodes a protein that is
a member of the small GTPase family. A mutation in this
gene results in an abnormal protein implicated in several
malignancies, including lung adenocarcinoma, ductal car-
cinoma of the pancreas and colorectal carcinoma among
others.
Chlamydophila pneumoniae and lung cancer
Lung cancer is the leading cause of cancer death in the
United States and many countries in the Western world.
In 2002, the most recent year for which statistics are avail-
able, 90,121 males and 67,509 females died from lung
cancer [37]. About 6 out of 10 people with lung cancer die
within 1 year of finding out they have lung cancer.
Between 7 and 8 will die within 2 years [38]. Although
patients may experience a partial or complete response to
treatment, most patients relapse and die. Increased dosage
of chemotherapy or length of treatment has not been ben-
eficial [39].
Chlamydophila (formerly Chlamydia) pneumoniae infection
has been implicated in several chronic lung diseases by
serology and direct antigen detection. Acute lower respira-
tory tract infection caused by C. pneumoniae seems often
to precede attacks of asthma in both children and adults
but is also involved in some exacerbations of chronic
bronchitis. More importantly it seems to be strongly asso-
ciated with chronic obstructive lung disease irrespective of
exacerbation status. Moreover, persistently elevated C.
pneumoniae antibody titers have been observed in sar-
coidosis and lung cancer [40].
C. pneumoniae is a Gram-negative bacillus and an intracel-
lular parasite that causes respiratory infection in more
than 50% of adults. The route of transmission is usually
by aerosol and in most cases these infections are mild. The
bacterium is, however, an important cause of pneumonia,
bronchitis, sinusitis, rhinitis and chronic obstructive pul-
monary disease [41]. Respiratory infections from C. pneu-
moniae vary in different countries and populations, being
endemic in the United States and epidemic in Scandina-
vian countries [19].
After acute infection the C. pneumoniae intracellular life
cycle is characterized by the development of metabolically
inert (and thus antibiotic resistant) atypical "persistent"
inclusions. These inclusions contain increased quantities
of chlamydial heat shock protein 60, a highly immuno-
genic protein implicated in the pathogenesis of chronic
chlamydial infections. The resulting clinical course is
acute symptomatic illness followed by chronic respiratory
symptoms.  Research also suggests that persistent C. pneu-
moniae inflammation correlates with increased risk of
lung cancer [16,17,19]. Prospective and retrospective
studies both report that individuals with elevated IgA anti-
body titers to this organism have 50% to 100% increased
lung cancer risk [15].
In a study by Kocazeybek et al. [19] the relationship
between chronic C. pneumoniae infection and lung carci-
noma was examined. A total of 123 patients who were
smokers and diagnosed with lung carcinoma based onPage 3 of 18
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were examined. 101 (82.1%) of the cases were male. 70
had small-cell, 28 squamous-cell and 7 large-cell carcino-
mas, while 18 had adenocarcinoma. 123 healthy controls
were matched to the cancer patients by age, gender, dura-
tion of smoking and locality.
Blood samples (5 ml) were withdrawn at the time of diag-
nosis (or enrollment for controls) and 1 month later. Val-
ues between IgG ≥512 and IgA ≥40 were set as the criteria
for chronic C. pneumoniae infections. In male patients
with lung carcinoma, IgG antibody titers of ≥512 and IgA
antibody titers of ≥40 were found at a higher rate than in
the control group, however, this ratio was not significant
for female patients. These elevations in antibody titers
were found in a total of 62 (50.4 %) cases, 54% of the
male patients and 36% of the female patients. Chronic C.
pneumoniae infections were seen statistically more often in
male patients with carcinoma who were aged 55 years or
younger than in controls (P < 0.001). No difference was
reported between male patients with lung carcinoma over
age 55 and controls or in blood titers between female
patients and controls.
The relationship between C. pneumoniae infection and
lung carcinoma was studied by Littman et al. [42] in a
large prospective case-control study to investigate whether
IgA antibody titers to C. pneumoniae were associated with
lung cancer risk. A total of 508 pairs were enrolled and
included both current and former smokers. Serum was
collected at baseline and annually thereafter. Antibody
determinations of each lung cancer subject and matched
control were tested simultaneously in the same titration
series in a blinded fashion. C. pneumoniae titers (IgA or
IgG) ≥16 were considered seropositive, which was consist-
ent with the cutoff used in other studies. Subjects were
matched by age, gender, and smoking status at baseline.
The median age of cases and controls was 59 years and
about half were women. All subjects were also examined
for demographic, lifestyle, dietary, and racial and ethnic
factors. Lung cancer subjects had a heavier smoking his-
tory than controls.
After adjusting for a history of chronic bronchitis or
emphysema, lung cancer subjects were more likely to have
IgA titers ≥16 (55.4% vs. 51.3%) and ≥256 (5.1% vs.
2.5%) to C. pneumoniae than controls. Individuals with
antibody tiers IgA ≥16 had 1.2 times the risk of lung can-
cer (95% confidence interval, 0.9–1.6) compared to those
with lower titers. Investigators reported a significant trend
(P = 0.007) of increasing odds ratios with increasing IgA
titers primarily due to an odds ratio of 2.8 (95% confi-
dence interval, 1.1–6.7) associated with titers ≥256. Ele-
vated IgA was reported with squamous cell carcinomas
and to a lesser extent, for small cell carcinomas and aden-
ocarcinomas. There was no evidence of a stronger associ-
ation with elevated IgG titers however. Subjects with race
not classified as White or Black were more likely to have
IgA titers ≥16. No significant differences in seropositivity
were found, however, based on smoking behaviors.
Streptococcus bovis and colorectal cancer
Colorectal cancer (CRC) is a common malignancy in
developed countries and is the 3rd most common cancer
in the United States [38]. Greater than 80% occur sporad-
ically [43]. The American Cancer Society estimates that
there will be about 104,950 new cases of colon cancer and
40,340 new cases of rectal cancer in 2005 in the United
States. Combined, they will cause about 56,290 deaths.
The risk of colon cancer increases after the age of 40 and
rises exponentially from the ages of 50 to 55. In fact, more
than 9 out of 10 people found to have colorectal cancer
are older than 50 [38].
Survival of CRC is related to the stage of disease at the
time of the initial diagnosis. Between 1985 and 1997,
death rates of colon cancer in the United States declined
slightly due to earlier detection of primary tumors, via
stool blood tests, sigmoidoscopy, colonoscopy, and
screening tests for serum carcinoembryonic antigen con-
centration (CEA) [44]. The 5-year survival rate for CRC
patients is greater than 90% when tumors are detected at
a localized early stage. After the cancer has spread region-
ally and involves adjacent organs or lymph nodes, the rate
drops to 40–65%; survival is less than 10% for patients
with distant metastases. Therefore, there is an urgent need
to develop effective treatment strategies to reduce morbid-
ity and mortality. Surgery is currently the primary treat-
ment modality for this disease. By the time the patient
presents with recurrent symptoms, however, the disease is
rarely curable by surgery even when combined with other
therapies [45].
Several species of bacteria have been linked to chronic
infections of the colon and increased risk of colon cancer
including Escherichia coli [46] and several streptococci
[47,48]. Recent studies, however, have validated earlier
findings of an association between colon cancer and Strep-
tococcus bovis [11,12]. As early as 1951, McCoy and Mason
[49] suggested a relationship between colonic carcinoma
and the presence of infectious endocarditis. It was not
until 1974 [50] that the association of Streptococcus bovis
and colonic neoplasia was recognized, as 25–80% of
patients who presented with a S. bovis bacteremia had a
colorectal tumor. The incidence of S. bovis associated
colon cancer has been determined as 18% to 62% [14].
S. bovis is a normal inhabitant of the human gastrointesti-
nal tract that can cause bacteremia, endocarditis, and uri-
nary infection [51]. Although S. bovis is the 2nd greatestPage 4 of 18
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is frequently associated with gastrointestinal lesions, espe-
cially carcinoma of the colon [12,51-53]. Notably, the
colonic neoplasia may arise years after the presentation of
the condition of bacteremia or infectious endocarditis
[12].
A retrospective review of forty-five documented cases of S
bovis bacteremia was conducted by Gold et al. [12]. Sub-
jects were identified by a search of computerized bacteri-
ology records from one tertiary referral hospital and 1
community hospital located in the same city. Patient
records were reviewed to identify the presence of colonic
neoplasia, the use of gastrointestinal endoscopy, and the
presence of gastrointestinal or extraintestinal malignan-
cies. Seventeen patients (41% of adult patients) under-
went colonoscopy. Colonic neoplasia was present in 16
patients (39% of adults). Invasive cancer was present in
13 patients (32% of adults), 8 of these had malignant
lesions arising within the gastrointestinal tract, 3 affecting
the colon and 5 patients had extraintestinal malignancies.
The authors concluded that S. bovis bacteremia was asso-
ciated with both colonic neoplasia and extracolonic
malignancy.
It has been demonstrated that S. bovis or its wall extracted
antigens (WEA) were able to promote carcinogenesis in
rats [12]. In one of these investigations a total of 10 adult
rats received i.p. injections of the carcinogen azoxymeth-
ane (AOM) (15 mg/kg body weight) once per week for 2
weeks. Fifteen days after the last injection of AOM (week
4) the rats were randomly divided into three groups.
Twice per week during 5 weeks, the rats received, by gav-
age either S. bovis (1010 bacteria Group I), WEA (100 µg
Group II) and controls (Group III).
One week after the last gavage (week 10), they found that
administration of either S. bovis or its antigens promoted
the progression of preneoplastic lesions. There were
increased formations of hyperproliferative aberrant
colonic crypts, enhanced expression of proliferation
markers and increased production of IL-8 in the colonic
mucosa. Normal rats treated with the bacteria did not
develop hyperplastic colonic crypts, however. The authors
concluded that S. bovis exerts its pathological activity in
the colonic mucosa only when preneoplastic lesions are
established.
Under identical experimental conditions Streptococcus gor-
donii was substituted for S. bovis. The number of preneo-
plastic lesions in the colon of S. gordonii-treated rats was
similar to rats treated with AOM alone (22 ± 2). The
authors suggested that S. bovis and its wall extracted anti-
gens, unlike S. gordonii, act as promoters of carcinogenesis
in a chemically-induced animal model.
In another investigation Biarc et al. [11] isolated 12 S.
bovis cell-associated proteins (S300) and WEA. Cells of the
human colonic epithelial cell line Caco-2 originally
derived from an adenocarcinoma were grown to conflu-
ence and allowed to differentiate. These cells were stimu-
lated with 200 ul of either S. bovis WEA (50 µg/ml) or cell-
associated proteins S300 (100 µl).
The purified S300 fraction was able to trigger the human
cell line and rat colonic mucosa to release chemokines
(human IL-8 or rat CINC/GRO) and prostaglandin E2
(PgE2). The 12 S. bovis proteins were highly effective in the
promotion of pre-neoplastic lesions in azoxymethane
treated rats. In fact the S300 proteins were able to induce
a 5-fold increase in PGE2 secretion from Caco-2 cells, as
compared with cells stimulated with WEA. The study
found that PGE2 release in the human cells correlated with
an over-expression of cyclooxygease-2 (COX-2).
Evidence has shown that over-expression of COX-2 has a
major role in mucosal inflammation [47] and is associ-
ated with inhibition of apoptosis [54] and enhancement
of angiogenesis [55], which favor cancer initiation and
development. It was reported by Biarc et al. [11] that S.
bovis proteins also promoted cell proliferation by trigger-
ing mitogen-activated protein kinases (MAPKs), which
can increase the incidence of cell transformation, the rate
of genetic mutations and up-regulate COX-2. The investi-
gators concluded that colonic bacteria such as S. bovis can
contribute to cancer development particularly in chronic
infection/inflammation diseases where bacterial compo-
nents may interfere with cell function [11].
Genetic predisposition to cancer-causing 
infections
Research has shown that some populations are genetically
predisposed to the infections that are associated with can-
cer and indeed have a higher risk of the cancer in question.
The exact mechanisms remain unclear [38].
E. coli, crohn's disease and colon cancer
Inflammatory bowel disease (IBD) includes both ulcera-
tive colitis (UC) and Crohn's disease (CD). Both of these
disorders have an increased risk of colorectal cancer
(CRC) [38,46,56]. Although colorectal cancer (CRC) in
individuals with IBD only accounts for 1–2% of all cases
of CRC in the general population, it is considered a seri-
ous complication of the disease and accounts for approx-
imately 15% of all deaths in patients with IBD. The
magnitude of the risk has been found to differ, however,
in population-based studies [56-58]. Recent figures sug-
gest that the risk of colon cancer for people with IBD
increases by 0.5–1.0% yearly, 8–10 years after diagnosis.
The magnitude of CRC risk also increases with early age at
IBD diagnosis, longer duration of symptoms, and extentPage 5 of 18
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tion and a higher risk of dysplasia-carcinoma progression
[56].
E. coli are found at higher levels in inflammatory bowel
disease (IBD), therefore, studies have examined the mech-
anisms that may explain this phenomenon. A cell culture
study by Martin et al [46] attempted to quantify and char-
acterize mucosa-associated and intramucosal bacteria,
particularly E. coli, in these inflammatory conditions.
Their hypothesis was that the disease-associated altera-
tions in mucosal glycosylation found in inflammatory
bowel disease and colon cancer might predispose to
altered recruitment of bacteria to the mucosa.
Mucosa-associated bacteria were isolated from biopsy
samples of Crohn's disease, (n = 14); ulcerative colitis, (n
= 21); noninflamed controls, (n = 24) and at surgical
resection of colon cancer, (n = 21). Results found that
mucosa-associated and intramucosal bacteria were cul-
tured more commonly in Crohn's disease (79%, P = 0.03;
and 71%, P < 0.01, respectively), and colon cancers (71%
and 57%) than in noninflamed controls (42% and 29%)
but not ulcerative colitis (38% and 48%). Mucosa-associ-
ated E. coli, which accounted for 53% of isolates, were
more common in Crohn's disease (6/14; 43%) than in
noninflamed controls (4/24, 17%), and intramucosal E.
coli more common in Crohn's disease (29%; controls,
9%).
E. coli expressed hemagglutinins in 39% of Crohn's cases
and 38% of cancers but only 4% of controls, and this cor-
related (P = 0.01) with adherence to embryonic intestinal
cells (I407) and colon adenocarcinoma cells (HT29).
Although close apposition of E. coli resulted in release of
pro-inflammatory cytokines, cellular invasion by bacteria
was not essential to this process [46].
Aspinell [59] suggested that the bacterial adherence found
by Martin et al. [46] might result from activation of viru-
lence genes following contact of the organisms with the
inflamed mucosal cells. Martin et al. [46] found, however,
that the mucosal isolates expressed of none of the known
virulence genes, other than adherence genes. Martin and
co-workers concluded that their findings supported a cen-
tral role for mucosally adherent bacteria in the pathogen-
esis of Crohn's disease. They postulated that similar, lower
grade, inflammatory changes could contribute to the risk
of sporadic cancer development [46].
The authors stated however that it was certainly possible
that the presence of the bacteria in the sub-mucus niche in
human Crohn's disease and colon cancer could have been
encouraged by disease-associated changes [46] in the
mucosa. If true, their findings would result from coloniza-
tion coincidental to the disease-associated alterations in
mucosal glycosylation found in inflammatory bowel dis-
ease and colon cancer.
A study conducted by Masseret et al.[60] examined the E.
coli strains isolated from patients with Crohn's disease
(CD) with chronic ileal lesions (n = 14), early endoscopic
recurrent lesions (n = 20), without endoscopic recurrence
(n = 7), and controls (n = 21). Genetically linked E coli
strains were isolated significantly more frequently from
patients with chronic and recurrent CD (24/33 patients)
than from controls (9/21) (p < 0.05). Most patients oper-
ated on for chronic ileal lesions (78.5%) harbored E coli
strains belonging to the same cluster (p < 0.002 v con-
trols). The prevalence of patients with early recurrent
lesions harboring E coli strains belonging to this cluster
was high but not significant. 21 of 26 strains isolated from
patients with active CD demonstrated adherent ability to
differentiated Caco-2 cells, indicating that most of the
genetically related strains shared a common virulence
trait. Comparison of E coli strains recovered from ulcer-
ated and healthy mucosa of patients operated on for CD
demonstrated in each patient that a single strain colo-
nized the intestinal mucosa. The authors suggested that
although a single E coli isolate was not found in Crohn's
ileal mucosa, some genotypes were more likely than oth-
ers to be associated with chronic or early recurrent ileal
lesions.
S. typhi and susceptible populations
As previously stated, certain populations have an
increased risk of gallbladder cancer (GC), however certain
individuals may be predisposed to S. typhi infection which
appears to increase the risk of GC. In an investigation by
deJong et al. [61], three unrelated individuals with severe,
idiopathic mycobacterial and Salmonella infections were
found to lack IL-12Rβ1 chain expression. Interleukin-12
(IL-12) is a cytokine that promotes cell-mediated immu-
nity to intracellular pathogens, such as S. typhi, by induc-
ing type 1 helper T cell (TH1) responses and interferon-γ
(IFN-γ) production. IL-12 binds to the high-affinity β1/β2
heterodimeric IL-12 receptor (IL-12R) complexes on T cell
and natural killer cells. The cells of these patients were
deficient in IL-12R signaling and IFN-γ production and
their remaining T cell responses were independent of
endogenous IL-12. IL-12Rβ1 sequence analysis revealed
genetic mutations that resulted in premature stop codons
in the extracellular domain. The genetic absence of IL12-
Rβ1 expression represented an immune deficiency in these
3 patients. Interestingly, these patients did not develop
any abnormal infections with other viral, bacterial, or fun-
gal pathogens. The defect in IFN-production and extreme
susceptibility to mycobacterial and Salmonella infections
in these patients appeared to be a direct result of their lack
of IL-12R expression and signaling. The authors con-Page 6 of 18
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Salmonella infections, however, suggested that the type-1
cytokine pathway was essential for controlling resistance
to the intracellular pathogens and that no redundant pro-
tective immune mechanism could compensate for this
deficiency.
Respiratory conditions and increased susceptibility to lung 
cancer
75–90% of people who develop lung cancer are smokers,
however, only a small proportion of smokers develop
lung cancer [42]. Hence, epidemiological studies such as
that of Littman et al [42] and Kocazeybek et al. [19] have
been conducted to more closely identify risk factors. Iden-
tifying genetic factors that increase a smoker's risk of
developing lung cancer may help scientists to better
understand the etiology of lung cancer and more effec-
tively target high-risk groups for screening. Additionally,
genetic factors have been identified that appear to predict
the prognosis of certain lung cancer patients [62]. For
example, mutations affecting the epidermal growth factor
receptor (EGFR) were significantly associated with specific
genetic alterations. Supervised clustering analysis based
on EGFR gene mutations elucidated a subgroup including
all EGFR gene mutated tumors, which showed signifi-
cantly shorter disease-free survival
To analyze the genetic alterations of primary lung adeno-
carcinoma in a high-throughput way, Shibata et al. [62]
used laser-capture micro-dissection of cancer cells and
array comparative genomic hybridization focusing on 800
chromosomal loci containing cancer-related genes. They
identified a large number of chromosomal numerical
alterations, including frequent amplifications. Three sub-
groups of lung adenocarcinoma were characterized by dis-
tinct genetic alterations and were associated with smoking
history and gender. The authors concluded that multiple
carcinogenic pathways exist; certain abnormalities appear
related to gender and smoking while others may impact
survival [62].
Bacterial strategies: cell cycle control and toxic 
warfare
Bacterial toxins can kill cells or at reduced levels alter cel-
lular processes that control proliferation, apoptosis and
differentiation. These alterations are associated with car-
cinogenesis and may either stimulate cellular aberrations
or inhibit normal cell controls. Cell-cycle inhibitors, such
as cytolethal distending toxins (CDTs) and the cycle
inhibiting factor (Cif), block mitosis and are thought to
compromise the immune system by inhibiting clonal
expansion of lymphocytes. In contrast, cell-cycle stimula-
tors such as the cytotoxic necrotizing factor (CNF) pro-
mote cellular proliferation and interfere with cell
differentiation [20].
Bacterial toxins that subvert the host eukaryotic cell cycle
have been classified as cyclomodulins. For example, CNF
is a cell-cycle stimulator released by certain bacteria, such
as E. coli. CNF triggers G1 – S transition and induces DNA
replication. The number of cells does not increase, how-
ever. The cells become multinucleated instead, perhaps by
the toxin's ability to inhibit cell differentiation and apop-
tosis [63,64].
Conversely the cytolethal distending toxin (CDT), as pre-
viously mentioned, is a cell-cycle inhibitor used by several
species of Gram-negative bacteria, including Campylo-
bacter jejuni and S. typhi. The CdtB unit of CDT is a DNAse
that creates double-stranded DNA breaks causing cell
cycle arrest, usually at the G2 checkpoint [65]. Cif is a cell
cycle inhibitor found in enteropathogenic (EPEC) and
enterohaemorrhagic (EHEC) E. coli. EPEC and EHEC
deliver this novel toxin by injecting it into the infected
epithelial cells. Cif arrests the cells at the G2/M phase
[66]causing unique alterations in the host cell that result
in attachment of the cytoskeleton to the host cell mem-
brane. This anchoring of the cytoskeleton inhibits mitosis,
causing cellular and nuclear enlargement. Although DNA
synthesis is initiated it does not lead to nuclear division.
Endoreduplicaton occurs resulting in cellular DNA con-
tent of 8–16n [20,66].
In a cell culture study, Haghjoo and Galán [65] found that
S. typhi produced a unique cdtB-dependent CDT that
required bacterial internalization into host cells. When
Cos-2 cells were transfected with S. typhi the effects of the
cdtB subunit were severe fragmentation of chromatin
characteristic of the CdtB subunit of CDT expressed by
other species. The authors proposed that S. typhi subse-
quent to internalization deviated from the usual endo-
cytic pathway that leads to lysosomes, reaching an
unusual membrane-bound compartment where it can
survive and replicate. It is possible that this unique CDT
may be involved in some aspects of the ability of S. typhi
to cause long, persistent infections in humans, because, at
least in other bacteria, this toxin has been shown to pos-
sess immunomodulatory activities.
Toxins are not the only strategy for evading the host's
immune system, however. An early study by Kilian et al.
[67] reported that some strains of Capnocytophaga ochra-
cea, an oral pathogen, are capable of hydrolytically
degrading immunoglobulin A subclass 1 found in the oral
cavity. This property may enhance colonization and inva-
sion of oral lesions which characterize many bacteremias
due to Capnocytophaga species. [67]. Shurin et al. [68]
obtained evidence that Capnocytophaga species inhibit
polymorphonuclear leukocyte migration; a means by
which these species may evade phagocytosis.Page 7 of 18
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offered by bacterial biofilms. An example of this phenom-
enon is provided by uropathic E. coli species whose bio-
films protect it from the immune system and making it
difficult to treat these infections effectively by antibiotics.
This has been demonstrated in bladder infections where
the same species is recovered after repeated flare-ups
thought to have been cleared by antibiotic therapy, sug-
gesting a subclinical infection that has become chronic
[69].
Bacterial site-specific colonization
Bacterial adherence is thought to be the first important
step in colonization. It is now recognized that bacteria
bind to and colonize host cells in a highly selective man-
ner via a "lock- and key" mechanism. This selectivity of
bacterial adhesion plays an important role in many infec-
tious processes, and an understanding of the mechanisms
involved could provide molecular explanations for the
innate resistance or susceptibility of hosts and tissues to
many infectious agents.
Regulators of complement activation (RCA proteins) pre-
vent the destructive consequences of inappropriate
immune activation. Decay-accelerating factor (CD55) is a
member of the RCA protein family that protects host cells
from complement damage and regulates the classical,
alternative and lectin pathways that converge to target
cells for destruction in all 3 pathways of the innate
immune system [70]. CD55 is expressed on all serum-
exposed cells. Perhaps due to its ubiquitous expression, it
is thought that bacterial pathogens, including uropatho-
genic Escherichia coli, use CD55 as a receptor prior to infec-
tion. Williams et al. [70] suggested that pathogens have
evolved to exploit the cellular roles of this molecule
thereby gaining immunological advantage [70].
The influence on E. coli binding of the two known single
amino acid polymorphisms within short consensus repeat
(SCR) domains of CD55 was examined by Pham et al.
[71] and Nowicki et al [72]. The bacterial strains sensitive
to a change in SCR3 were found to be insensitive to
changes in SCR4 and vice versa, suggesting that multiple,
independent binding sites of CD55 were used by different
bacterial strains. Evidence from those investigations sug-
gested that E. coli strains sensitive to changes in one bind-
ing domain were not affected by changes in other
domains.  Furthermore, the use of CD55 as a receptor by
a variety of uropathic E. coli was found to correlate with
symptomatic infections [71,72]. Evidence from those
investigations indicated the extraordinary degree of site-
specific colonization of these closely related strains.
Bacteria associated with a coincidental or 
diagnostic role
Each year nearly 30,000 Americans are diagnosed with
oral cancer [73,74]. Over 90% of these malignancies are
oral squamous cell carcinoma (OSCC). Despite advances
in surgery, radiation and chemotherapy, the five-year sur-
vival rate is 54%, one of the lowest of the major cancer
sites and this rate has not improved significantly in recent
decades [38,75,76]. The disease kills one person every
hour – more people than cervical cancer, Hodgkin's dis-
ease, or malignant melanoma [38]. Notably, incidence in
young adults (<40 years) is increasing in the U.S. [8,10]
and worldwide [9,77]. The World Health Organization
predicts a continuing worldwide increase in oral cancer
over the next several decades [78].
Early detection followed by appropriate treatment,
increases cure rates to about 80%, and greatly improves
the quality of life by minimizing extensive, debilitating
treatments [75]. Oral cancer is asymptomatic in its early
stages, however, and in spite of the accessibility of the oral
cavity to direct examination, these malignancies are often
not detected until a late stage [79-81]. Oral cancer is unu-
sual in that it carries a high risk of second primary tumors.
Patients who survive a first cancer of the oral cavity have
up to a 20-fold increased risk of developing a second pri-
mary oral cancer. The heightened risk can last 5–10 years,
sometimes longer [82].
In response to the difficulties in effectively treating oral
cancer, research studies are focusing on prevention and
early diagnostics. Some of these studies have found that
OSCC lesions are colonized by an altered microbiota
[83,84]. Other investigations have found bacterial DNA or
live organisms within oral cancer tissues [85,86]. The true
nature of the relationships between oral bacteria and oral
or esophageal cancers is, however, currently unknown.
PCR techniques have been used to seek the DNA of bacte-
rial species in head and neck cancer tissues. Sasaki et al.
[85] found S. anginosus DNA sequences in tissue samples
from 127 cancer patients. Tissues examined included
esophageal cancer, gastric cancer tissues, and dysplasia of
the esophagus from esophageal cancer patients. No S.
anginosus DNA was found in noncancerous esophagus or
stomach samples. However, the degree of S. anginosus
infection in biopsied tissues was much more obvious in
the dysplastic and cancerous sections than in the noncan-
cerous portions of the esophagus suggesting that S. angi-
nosus infection occurred at an early stage of esophageal
cancer. The authors suggested that S. anginosus could play
a significant role in the carcinogenic process of most cases
of esophageal cancer and some cases of gastric cancer by
causing inflammation.Page 8 of 18
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the esophagus contained a detectable level of S. anginosus
DNA, but only 5 of 38 (13%) of oral cancer had detectable
DNA levels of this organism. The quantity of S. anginosus
DNA in the esophageal cancer tissues was significantly
higher than in oral cancer. The maximum amount of S.
anginosus DNA was approximately 10 times higher in
esophageal than in oral cancer tissues. In addition, none
of the 5 different oral cancer sites (floor of mouth, maxil-
lary or mandibular gingiva, buccal mucosa, and tongue)
showed significant signs of S. anginosus infection. Most
non-cancerous tissues of the esophagus and tongue
showed an undetectable level of S. anginosus. The authors
concluded that S. anginosus is associated with esophageal
cancer, but is not closely related with oral cancer.
In a previous study by Mager et al. [87] it was determined
that the salivary microbiota was similar to that of the oral
soft tissues. Therefore, the investigators examined whether
the salivary counts of 40 common oral bacteria in subjects
with an oral squamous cell carcinoma (OSCC) lesion
would differ from those found in cancer-free (OSCC-free)
controls [83]. Unstimulated saliva samples were collected
from 229 OSCC-free and 45 OSCC subjects and evaluated
for their content of 40 common oral bacteria using check-
erboard DNA-DNA hybridization.
DNA counts per ml saliva were determined for each spe-
cies, averaged across subjects in the 2 subject groups, and
the significance of differences between groups determined
using the Mann-Whitney test and adjusted for multiple
comparisons. The diagnostic sensitivity and specificity in
detection of OSCC by levels of salivary organisms were
computed and comparisons made separately between a
non-matched group of 45 OSCC subjects and 229 con-
trols and a group of 45 OSCC subjects and 45 controls
matched by age, gender and smoking history.
Counts of 3 of the 40 species tested, Capnocytophaga gingi-
valis, Prevotella melaninogenica and Streptococcus mitis, were
elevated in the saliva of individuals with OSCC (p <
0.001). When tested as diagnostic markers the 3 species
were found to predict 80% of cancer cases (sensitivity)
while excluding 83% of controls (specificity) in the non-
matched group. Diagnostic sensitivity and specificity in
the matched group were 80% and 82% respectively. These
findings suggest that high salivary counts of C. gingivalis,
P. melaninogenica and S. mitis could be diagnostic indica-
tors of OSCC.
The reasons for the differences in colonization patterns of
specific bacterial species at different host locations are
only partially understood. These reasons include differ-
ences in nutrient availability, competition among species
for binding sites, inter-species antagonisms or coopera-
tions, and the differences in receptors present on different
tissues that permit binding by specific adhesins possessed
by different species. Other factors that may partly explain
the unfavorable microbial shifts observed in oral carci-
noma surface biofilms are a compromised host response
or the irregularity of the lesion surface providing stagnant
habitats.
The most intensely studied of these possibilities has been
the specificity in adhesion of different bacterial species to
receptors on oral soft tissues. Many studies have focused
on fimbriae-mediated adhesion and adhesins in the
adherence of different oral species to oral epithelial cells
[88-91]. As a universal trait of cancer cells is alterations in
cell surface receptors, studies have examined the coloniza-
tion of healthy and cancerous epithelia [83,85-87,92].
A study by Neeser et al. [92] examined the binding of a
common oral bacterial species, Streptococcus sanguis OMZ
9 to healthy and cancerous buccal cell lines. Results
showed that S. sanguis bound to exfoliated human buccal
epithelial cells in a sialic acid-sensitive manner. The desi-
alylation of such cells invariably abolished adhesion of S.
sanguis to the epithelial cell surface. The resialylation of
desialylated HBEC with CMP-sialic acid and
Galß1,3GalNAc α2,3-sialyltransferase specific for O-gly-
cans restores the receptor function for S. sanguis OMZ 9,
whereas a similar cell resialylation with the
Galß1,4GlcNAc α2,6-sialyltmnsferase specific for N-gly-
cans is without effect. These findings suggested that a 23
kDa cell surface glycoprotein bearing a carbohydrate
sequence, NeuNAc alpha 2-3Gal beta 1-3GalNAc O-
linked sugar chains, is recognized by S. sanguis on exfoli-
ated human buccal epithelial cells. In similar experiments
carried out with a buccal carcinoma cell line termed
SqCC/Y1, S. sanguis did not attach in great numbers to cul-
tured tumor cells. These cells were shown to not express
the membrane glycoprotein bearing alpha 2,3-sialylated
O-linked carbohydrate chains.
Aberrations in the cell surface carbohydrate structures
have now been established as a universal characteristic of
malignant transformation of cells, and cancer has been
referred to as a molecular disease of the cell membrane
glycoconjugates [93,94]. Thus, changes in the tumor cell
surface structure could alter the adhesion of different spe-
cies of oral bacteria. Notably, even species within the same
genera, such as streptococci, have been found to differ in
their colonization of healthy and cancerous oral tissues
[83,87].
Bacteria and the prevention or treatment of 
cancer
Evidence is mounting that certain species of bacteria or
their toxins may indeed have a protective or curative rolePage 9 of 18
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role of a bacterial species include: (1) colonization lowers
the risk of a certain cancer; (2) elimination or absence of
colonization raises the risk, or (3) introduction of the bac-
teria or its toxins cures or causes remission of the cancer.
Tumors and coley's toxins
Spontaneous tumor regression has followed severe bacte-
rial, fungal, viral and protozoal infections. For hundreds
of years this phenomenon inspired the development of
the earliest cancer therapies. Reports of spontaneous
remissions of advanced cancers infections can be found in
the late nineteenth and early twentieth centuries. Many of
these unexplained cures followed bacterial infections
accompanied by high fevers.
An American surgeon, Dr. William Coley began the first
well-documented use of bacteria and their toxins to treat
end stage cancers. Coley first used live Streptococcus pyo-
genes cultures. Problems with the predictability of patient
responses caused him to develop a safer vaccine in the late
1800's composed of two killed bacterial species, S. pyo-
genes and Serratia marcescens. In this way he could simu-
late an infection with the accompanying fever without the
risk of an actual infection [95,96].
Coley's vaccine was widely used to successfully treat sarco-
mas, carcinomas, lymphomas, melanomas and myelo-
mas. Complete, prolonged regression of advanced
malignancy was documented in many cases. The com-
bined reports of Coley and others estimated the 5-year
survival rate at 80% in malignancies for which no treat-
ment existed. Even in patients considered in the terminal
stages of cancer some remarkable recoveries were reported
with the patient often outliving the cancer [97].
Coley considered 4 points critical to success: (1) initiation
of a naturally occurring infection with fever, (2) avoid-
ance of immune tolerance by gradually increasing the dos-
age, (3) directly injecting the vaccine into the tumor when
accessible, and (4) a minimum of 6 months of injections
to avoid recurrences. Today little credence is given to the
febrile response in fighting cancer [96,97].
A retrospective study was conducted in 1999 to compare
the 10 year survival rate of patients treated by Coley's vac-
cine with modern conventional therapies. Richardson et
al. [95] tried to match 128 of Coley's cases with 1,675 con-
trols from the Surveillance Epidemiology End Result
(SEER) cancer registry. The 2 populations were matched
by age, gender, ethnicity, stage and radiation treatment
status. Limitations included sample size and staging of
patients receiving Coley's vaccine. The authors concluded
that "Given the tremendous advances in surgical tech-
niques and medicine in general, any cohort of modern
patients should be expected to fare better than patients
treated 50 or more years ago. Yet no such statistical advan-
tage for the modern group was observed in this study."
These findings were supported by case reports of sponta-
neous remissions or significant benefits when accidental
infections occurred [98-100].
What role may a febrile response play in the remission of
a tumor? Hobohm [101] offers the following hypothesis.
Fever causes a cascade of events of inflammatory factors
which activate resting dendritic cells (DC) that lead to the
activation of T-cells. Cancer-cell specific T-cells usually
remain in a state of anergy, most likely due to the absence
of danger signals that usually accompany tissue destruc-
tion and inflammation upon acute infection [102]. A
feverish bacterial infection may have a 3-fold beneficial
effect. First, many infectious agents release endotoxins,
like LPS, induce inflammatory cytokines and stimulate
DC. Second, both thymocyte proliferation and generation
of allo-specific CTL are increased with temperature in
vitro [103]. Third, the vasculature of a tumor is more frag-
ile than that of normal tissues and therefore more prone
to destruction by the immune response. An infection
causing hemorrhagic necrosis could trigger febrile col-
lapse of the tumor vasculature [104,105]. Interestingly,
the affinity of certain streptococci for binding to fibrino-
gen and fibrin may account for the 'homing' of bacterial
enzymes to tumors as these cells are abundant in such
proteins [106].
The mechanism by which infection cures cancer has been
investigated. It has been suggested by Zacharski and
Sukhatme [96] that the tumor regression observed by
Coley and others is due to the activation of plasminogen.
For example when the streptococcal spreading factor
known as streptokinase (SK) combines with host plas-
minogen, plasmin is released. Plasmin triggers protease
cascades that degrade plasma and extracellular matrix pro-
teins. These mechanisms of degradation are toxic to
tumor cells, disrupt the tumor extracellular matrix, alter
tumor growth and inhibit metastasis [96]. The notion that
plasminogen activators like SK might result in the remis-
sions reported by Coley is appealing as they appear to
spare healthy cells while attacking tumors. Zacharski et al.
[107] hypothesized that although the potent enzymes
produced by plasminogen activation may have a direct
effect on cancer cells it was more likely they disrupted the
cell-extracellular matrix of the tumor.
Investigators report that the traditional best treatment
options for some candidate tumor types, such as advanced
soft tissue sarcomas, breast cancer and melanoma, have
not improved patient outcome substantially since Coley's
day [96,108,109]. Currently, biologic response modifier
therapies have moved beyond the nonspecific immuno-Page 10 of 18
(page number not for citation purposes)
Journal of Translational Medicine 2006, 4:14 http://www.translational-medicine.com/content/4/1/14therapy of Coley's era and laid the foundation for today's
approaches. Zarcharski and Sukhatme [96] suggest that
the early success of Coley's toxins are leading to therapies
that engage the host's immune system against an individ-
ual's tumor offering new hope for cancer patients.
Autologous tumor cell vaccine therapy is an example of
this new approach to cancer treatment. These vaccines dif-
fer markedly from conventional cytotoxic drug therapy
that affect both normal and tumor cells. Tumor vaccines
stimulate an individual's cell-mediated immune response
by targeting the patient's tumor antigens. While efficacy of
standard chemotherapy relates to the dose of the drug, the
efficacy of a tumor vaccine is more complex, involving
host-vaccine interactions [110]. These include: (1) immu-
nogenicity of the vaccine regarding tumor-associated anti-
gens as opposed to self; (2) the host's immune response
in terms of immune recognition and effector mecha-
nisms; and (3) the development of host systemic cell-
mediated immunity, including long-term immunologic
memory, (3–5 years). Therefore, the potency of the vac-
cine is not determined by immunogenicity alone but by
its ability to induce the host anti-tumor response [110].
Bacillus calmette-guérin and autologous tumor cell 
vaccine vs. colon cancer
Certain tumor antigens are, however, normally weak
immunogens. Therefore the use of adjuvants and the
intradermal route of injection have, in some cases, pro-
duced an optimum antigenic vaccine. These adjuvant vac-
cines have induced effective host recognition of tumor-
associated antigens and improved patient survival. For
example, preliminary evidence by Hoover et al [111] sug-
gested that active specific immunotherapy (ASI) of colon
cancer using autologous tumor cell vaccines had potential
in improving recurrence-free interval and survival. ASI
assumes there are distinct tumor antigens on an individ-
ual's cancer cells that are either absent or in lower concen-
tration on normal cells. The vaccine attempted to
stimulate host's immune defenses against tumor-associ-
ated antigens by enhancing the immunogenicity of the
patient's own tumor cells with an immunomodulating
adjuvant, such as Bacillus Calmette-Guérin (BCG).
In a study by Hoover et al. [111] 80 eligible subjects with
colon (47) or rectal (33) cancer were enrolled into a pro-
spectively randomized, controlled clinical trial of active
specific immunotherapy (ASI). An autologous tumor cell-
Bacillus Calmette- Guerin (BCG) vaccine was used to
determine whether ASI could improve disease- free status
and survival. Eligible subjects had colon or rectal cancers
extending through the bowel wall or had positive lymph
nodes providing adequate cells from the primary tumor.
Wide surgical removal of all tumors was performed with
histologically proven clear margins and removal of
involved lymph nodes. Prior to randomization individu-
als were screened for metastatic disease. Colon cancer and
rectal cancer subjects were in separate but parallel studies
and randomized into groups treated by resection alone or
resection plus ASI. 3–4 weeks following surgery, both con-
trols and treatment subjects were skin tested for immune
competence and sensitivity to tuberculin purified protein
derivative (PPD). Vaccines were begun in the ASI treat-
ment group 4–5 weeks following surgery to allow for ade-
quate immune recovery from surgery and anesthesia. A
total of 24 colon and 17 rectal subjects composed the
treatment group. With a median follow-up of 93 months,
there was a significant improvement in survival (two-
sided P = .02; hazards ratio, 3.97) and disease-free survival
(two-sided P = .039; hazards ratio, 2.67) in all eligible
colon cancer patients who received ASI. With a median
follow-up of 58 months, no benefits were seen in patients
with rectal cancer who received ASI. The authors con-
cluded that the study suggested that ASI may be beneficial
to patients with colon cancer.
In 2005, Uyl-de Groot et al. [110] conducted a multi-
center, randomized controlled phase III clinical trial with
Stage II and III colon cancer patients using ASI. Autolo-
gous tumor cells were used with the immunomodulating
adjuvant Bacillus Calmette-Guérin (BCG) in a vaccine
(OncoVAX®). Patients were randomized to receive either
OncoVAX® or no therapy after surgical resection of the pri-
mary tumor. The vaccine was processed within 48 h after
surgery in order to have viable, metabolically active,
autologous tumor cells.
Analysis of prognostic benefit with a 5.8 year median fol-
low-up, showed that the beneficial effects of OncoVAX®
were statistically significant at all endpoints including
recurrence-free interval, overall survival, and recurrence-
free survival in Stage II colon cancer patients. Surgery
alone cures 65% of Stage II colon cancer patients. For the
remaining patients, OncoVAX® in an adjuvant setting sig-
nificantly prolongs recurrence-free interval and signifi-
cantly improves 5-year overall survival and recurrence-free
survival. Unfortunately, no statistically significant prog-
nostic benefits were achieved in Stage III patients [110].
Immunization with bacillus calmette-guérin vs. lung cancer
Grant et al [39] hypothesized that optimal chemotherapy
with or without radiation followed by active immuniza-
tion could eliminate microscopic residual disease and
prolong survival. Immunization with GD3, a ganglioside
expressed on the surface of most small cell lung cancers
(SCLC) had not evoked a strong immune response. There-
fore BEC2, a large xenogenic protein which mimics GD3,
was judged to be a good immunogenic candidate. This
approach had proven successful in extending the lives of
melanoma patients [112].Page 11 of 18
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ing 5 dose levels of BEC2. The study population consisted
of 15 patients with small cell lung cancer (SCLC). All sub-
jects had completed standard therapy and had achieved a
partial or complete response. Patients received a series of
five intradermal immunizations consisting of 2.5 mg of
BEC2 plus BCG over a 10-week period. Blood was col-
lected for serological analysis, and outcome was moni-
tored. All patients developed anti-BEC2 antibodies,
despite having received chemotherapy with or without
thoracic radiation. Anti-GD3 antibodies were detected in
five patients, including those with the longest relapse-free
survival. The median relapse-free survival for patients with
extensive stage disease was 10.6 months. In patients with
limited stage disease a median relapse-free survival had
not been reached with a follow-up of >47 months and
only one of the 7 patients in this group relapsed. The
authors reported that immunization of SCLC patients
using BEC2 plus BCG after standard therapy could induce
anti-GD3 antibodies and was safe. The survival and
relapse-free survival in this group of patients was substan-
tially better than those observed in similar patients receiv-
ing standard therapy.
A Phase III trial was conducted to evaluate BEC2 plus BCG
as adjuvant therapy for limited small-cell carcinoma after
chemotherapy and irradiation [114]. A total of 515 sub-
jects were randomly assigned. Unfortunately, in this trial
there was no improvement in survival, progression-free
survival, or quality of life in subjects that were vaccinated.
A trend toward prolonged survival was observed in the
one third of subjects who developed a humoral response
(p = 0.085), however.
The effectiveness of vaccines for several cancers was exam-
ined in a series of investigations. Xiang et al. [115] tested
vaccines for human melanoma using the mutant S. typhi
strain SL7207 as a DNA carrier. Tolerance against self-anti-
gens was broken by genetically fusing ubiquitin with
MHC I derivatives. Another approach coupled tumor-spe-
cific antibodies to functional IL-2. This combination in
addition to oral vaccination with plasmid-encoded tumor
antigens significantly enhanced protection against carci-
noma of the colon [116], carcinoma of the lung [117] and
melanoma [118]. Unstable cancer cells provided a chal-
lenge, however. Interestingly, this was overcome by target-
ing stable, proliferating endothelial cells of the tumor
vasculature. This novel approach effectively inhibited ang-
iogenesis [119].
Helicobacter pylori and esophageal adenocarcinoma
In industrialized countries the incidence of H pylori has
been steadily decreasing [120]. The incidence of esopha-
geal cancer (EA), however, is increasing [121]. Surpris-
ingly, there is evidence that these two trends may be
related. Several studies have determined that virulent
strains of H pylori are found less commonly among
patients with Barrett's esophagus and EA when compared
with controls [122-124]. This led to studies that found
positive associations among the increased incidence of
obesity, GORD, Barrett's esophagus and EA [125].
Recently, a nested case-control study was conducted by de
Martel et al [126] to assess the association between H.
pylori infection and the risk of development of EA. Of a
total of 128,992 members of an integrated health care sys-
tem who had participated in a multiphasic health checkup
(MHC) during 1964–1969, 52 patients developed EA dur-
ing follow-up. Three randomly chosen control subjects
from the MHC cohort were matched to each cancer sub-
ject, on the basis of age, gender, race, date and site of the
MHC. Data on cigarette smoking, alcohol consumption,
body mass index (BMI), and education level were
obtained. Serum samples collected at the MHC were
tested for IgG antibodies to H. pylori and to the H. pylori
CagA antigen associated with H. pylori virulence.
Subjects with H. pylori infections were less likely than
uninfected subjects to develop EA odds ratio (OR, 0.37)
95% confidence interval (CI, 0.16–0.88). This significant
association was restricted to cancer subjects and control
subjects <50 years old (OR, 0.20) (95% CI, 0.06–0.68).
Interestingly, in patients with H. pylori infections, the OR
for EA in those who tested positive for IgG antibodies to
the CagA protein was similar to that for those who tested
negative for it. BMI ≥25 and cigarette smoking, however,
were strong independent risk factors for EA. The authors
found, however, that the absence of H. pylori infection,
independent of cigarette smoking and BMI, was associ-
ated with an increase in the risk of development of EA
[126].
An epidemiological study in Sweden sought to determine
whether BMI was associated with esophageal malignan-
cies compared to gastric adenocarcinoma and controls. In
a nationwide, population-based case-control study by
Lagergren et al [127], between 1995 through 1997, a total
of 189 patients with adenocarcinoma of the esophagus
and 262 patients with adenocarcinoma of the gastric car-
dia were enrolled. These patients were compared with 167
patients with incident esophageal squamous cell carci-
noma and 820 healthy controls.
Odds ratios were determined from BMI and cancer case-
control status and ratios estimated the relative risk for the
two adenocarcinomas studied. Calculations used multi-
variate logistic regression with adjustment for potential
confounding factors. The adjusted odds ratio was 7.6
(95% CI, 3.8 to 15.2) among persons in the highest BMI
quartile compared with persons in the lowest. Obese per-Page 12 of 18
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16.2 (CI, 6.3 to 41.4) compared with the leanest persons
(persons with a BMI<22 kg/m2). The odds ratio for
patients with cardia adenocarcinoma was 2.3 (CI, 1.5 to
3.6) in those in the highest BMI quartile compared with
those in the lowest BMI quartile and 4.3 (CI, 2.1 to 8.7)
among obese persons. Although a strong dose-dependent
relation existed between BMI and esophageal adenocarci-
noma, esophageal squamous-cell carcinoma was not
associated with BMI. A modest but significant increase in
intragastric acidity was also observed following the cure of
H pylori infection which the authors postulated could con-
tribute to gastroesophageal reflux disease (GORD).
The incidence of EA has increased rapidly over the last 30
years. During this period, the prevalence of Helicobacter
pylori has decreased. Trends of increasing esophageal ade-
nocarcinoma can be linked causally to increasing GORD
which can be linked to an increasingly obese population.
There appeared to be no plausible biological mechanism
of association between H pylori, obesity, and GORD until
studies of ghrelin, however.
Ghrelin was the first circulating hormone demonstrated
to stimulate food intake in man. This peptide is produced
in the stomach and regulates appetite, food intake, and
body composition. The effects of ghrelin were examined
in H pylori positive asymptomatic subjects by several
investigators [128-130]. In a randomized double-blind
cross-over study, by Wren et al. [129], ghrelin was shown
to acutely enhance appetite and increase food intake in 9
healthy human subjects. There was a clear-cut increase in
calories consumed by every individual from a free-choice
buffet (mean increase 28 +/- 3.9%, p < 0.001) during
ghrelin versus saline infusions. Furthermore, visual ana-
logue scores for appetite were greater during ghrelin com-
pared to saline infusion. Ghrelin had no effect on gastric
emptying, however. The authors concluded that endog-
enous ghrelin was a potentially important new regulator
of the complex systems controlling food intake and body
weight.
Evidence is accumulating that ghrelin may explain the rel-
ative rarity of H. pylori among patients with Barrett's
esophagus and EA. Findings from these studies and others
support the notion that H. pylori may have a "protective"
effect against EA [122,124]. Studies have found that cur-
ing H pylori infection increased plasma ghrelin in healthy
asymptomatic subjects which may lead to increased appe-
tite, weight gain and contribute to the increasing obesity
seen in Western populations where the prevalence of H
pylori is low. This evidence supports the notion that
decreasing incidence of H pylori infection may lead to
increased levels of plasma ghrelin and that this hormone
appears to be a factor in increasing obesity which elevates
the risk of GORD which is positively associated with Bar-
rett's esophagus and increased risk of esophageal adeno-
carcinoma. It appears that the absence of H. pylori
infection may be one of several factors that leads to the
increased incidence in EA effect observed in Western pop-
ulations.
The implications for treatment of individuals with H.
pylori infection were addressed by Nakajima and Hattori
[131]. They systematically reviewed the literature and esti-
mated the expected annual incidence of esophageal or
gastric cancer with and without eradication of H. pylori
infection in patients with chronic atrophic gastritis. The
expected annual incidence of gastric cancer in patients
with corpus atrophy with persistent infection was at least
5.8-fold higher than that for esophageal adenocarcinoma
after the eradication of infection at all ages. Even for
patients with accompanying reflux esophagitis or Barrett's
esophagus, the incidence of gastric adenocarcinoma with
persistent infection was higher than that of esophageal
adenocarcinoma after eradication of infection. The
authors concluded, therefore, that if eradication of infec-
tion lowers the incidence of gastric cancer, it should be
recommended for patients with corpus atrophy at all ages
irrespective of the presence of reflux esophagitis or Bar-
rett's esophagus, especially in populations having a high
prevalence of gastric cancer [131].
In summary, increased BMI has been linked with the elim-
ination of H. pylori infection. As the sphincter mechanism
at the esophagogastric junction is weakened by weight it
is not surprising that obese individuals have a higher inci-
dence of gastric reflux or GORD [127]. GORD may lead to
the development of Barrett's esophagus, which increases
the risk of EA by 40-fold [132,133]. The study by Lager-
gren [127] provides evidence that these associations may
be related as increasing body mass was associated with a
stepwise increase in the risk of EA. If eradication of H.
pylori infection lowers the incidence of gastric cancer,
however, it should be recommended for patients with cor-
pus atrophy at all ages irrespective of the presence of reflux
esophagitis or Barrett's esophagus, especially in popula-
tions having a high prevalence of gastric cancer [131].
Attenuated bacteria: Promising carriers of DNA vaccines
Attenuated bacteria will enhance stimulation of the innate
immune system yet increase the safety of a vaccine, [134]
therefore they may be ideal for the delivery of vaccines.
Animal studies have shown that attenuated S. typhimurium
strains can successfully deliver a variety of genetically
engineered DNA vaccine plasmids for therapeutic vaccina-
tion of mice against model tumors [117,118,135].
The identification of bacterial "carriers" for DNA vaccines
that target cancer cells by site-specific colonization mayPage 13 of 18
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cells [136]. Colonization of these species may be consid-
ered coincidental to favorable conditions provided by the
tumor yet prove clinically useful. Ultimately, however, the
safety and efficacy of recombinant therapeutic agents
expressed by plasmids must be conducted in appropriate
animal models.
Conclusion
Cancer is commonly defined as the uncontrolled growth
of abnormal cells that have accumulated enough DNA
damage to be freed from the normal restraints of the cell
cycle. Several pathogenic bacteria, particularly those that
can establish a persistent, infection, can promote or initi-
ate abnormal cell growth by evading the immune system
or suppressing apoptosis [54,137]. Intracellular patho-
gens survive by evading the ability of the host to identify
them as foreign. Other species or their toxins can alter
host cell cycles or stimulate the production of inflamma-
tory substances linked to DNA damage [120].
The highly site-specific adherence of bacteria involves
binding species-specific adhesions to the required cell sur-
face receptors. The role of species that colonize tumors
could be causal, coincidental or potentially protective. If
adhesion to the tumor in question is highly sensitive and
specific it may be ideal not only in diagnosing the pres-
ence of a malignancy but also in delivering the appropri-
ate therapy.
The bacterial species associated with cancer etiology are
diverse; however, the infections they cause share common
characteristics [18]. The time between acquiring the infec-
tion and cancer development is most often years or even
decades as seen in cancers associated with H. pylori, S. typhi
and S. bovis infections. Chronic interactions between the
infective agent and immune response and/or a susceptible
host appear to contribute to carcinogenesis [8,18,38,138].
Preventing or treating the infection may prevent the can-
cer in question. Notably, the vast majority of individuals
infected with a cancer-causing species will not develop
cancer [18].
Evidence suggests that certain individuals are more sus-
ceptible to infections linked to cancer development and
that the incidence of certain cancers varies among popula-
tions. For example, gallbladder cancer is 3 times higher in
females as in males in all populations [26]. Lung cancer is
highest in populations that smoke however, only a small
proportion of smokers develop lung cancer [42].
Although colon cancer is the 3rd highest cancer in the
United States, individuals with IBD have a far greater risk
of colorectal cancer than individuals without IBD [56-58].
A screening test for oral cancer based on salivary counts of
bacterial species is appealing. Currently saliva is meeting
the demand for inexpensive, non-invasive, and easy-to-
use diagnostic aids for oral and systemic diseases, and for
assessing risk behaviors such as tobacco and alcohol use.
Although the colonization of certain bacterial species may
be coincidental to favorable conditions provided by
OSCC, increased numbers of certain salivary species may
be clinically useful if shown to be a signature of oral can-
cer and if sensitivity and specificity are improved.
Successful treatment for cancers was reported by Dr. Coley
and others one hundred years ago. His approach of using
killed bacterial vaccines was surprisingly effective in some
patients even in the latest stages of cancer. Dr. Coley
believed that the human immune system had the power
to cure cancers if properly stimulated. Today, some inves-
tigators agree and have designed new treatments that
stimulate the immune system to recognize and target the
lesion. Recent reports suggest that attenuated bacterial
vaccines can safely and effectively deliver plasmids encod-
ing tumor self antigens. These studies have reported suc-
cessful treatment of certain cancers and prevention of
recurrences [39,110,111]. Cancer vaccines although
promising, present significant challenges. These include
identification of highly effective bacterial strains and their
attenuations, addressing safety issues and the problem of
overcoming the peripheral T cell tolerance against tumor
self-antigens [139]. Further, the response to vaccines will
likely vary among individuals.
It appears that colonization by certain bacteria may
reduce the risk of cancer in some populations. The epide-
miological trends of esophageal adenocarcinoma and
Helicobacter pylori infection have stimulated research into
whether these may be coincidental or due to an inverse
association. Intriguing results suggest there is an associa-
tion represented by a complex continuum that begins
with curing infections of virulent strains of H. pylori. The
absence of H. pylori appears to elevate ghrelin which stim-
ulates increased appetite in some individuals. High ghre-
lin levels appear to be associated with increased incidence
of obesity.  Obesity is reported to be a contributing factor
in GORD.  Finally, GORD may lead to Barrett's esophagus
which increases the risk of esophageal adenocarcinoma. If
these relationships can be proven, then the colonization
of this species and its seemingly negative association with
EA may be more clearly understood.
In summary, recent research has uncovered a great deal of
information regarding the bacterial mechanisms used to
cause, colonize or cure cancer, however, many questions
remain. For example, do the bacteria in question initiate,
promote, or merely show affinity for the neoplasm? Con-
versely does cancer weaken the host which facilitatesPage 14 of 18
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nization of certain bacteria for a tumor be clinically useful
in diagnosis or treatment? Could attenuated bacteria be
used in vaccines to safely and effectively deliver therapeu-
tic agents? The continued exploration of these questions
will bring research ever closer to the prevention, early
diagnosis and truly effective treatment of this scourge of
mankind.
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